Ayşe Nur BÜLBÜL, Eda EVGEN TÜLÜCEOĞLU, Nejat Önder ÖZTÜRK, Nilüfer Şahin CALAPOĞLU, Taner GONCA, Mustafa CALAPOĞLU

Serum Oreksin-A Seviyelerinin Obezite ile İlişkisi: Kesitsel İlişkilendirme Çalışması

Amaç: Çalışmanın amacı, çalışma bölgesinde obez erişkinkohortunda, oreksin-A hormonunun obezite ile ilişkisinideğerlendirmektir.Materyal-Metot: Çalışmaya, Süleyman Demirel üniversitesiTıp Fakültesi ve Isparta Devlet Hastanesi Göğüs HastalıklarıUyku Laboratuvarlarına başvuran 20-59 yaş arasındaki258 birey dahil edildi. Vücut kitle indekslerine (VKİ) göre,bireyler beş kategoriye (normal kilolu, fazla kilolu, orta obez,ağır obez ve morbid obez) ayrıldı. Bireylerden alınan kanörneklerinde, ticari olarak temin edilebilen analitik sistemlerkullanılarak plazma oreksin-A, C-reaktif protein (CRP) vedüşük dansiteli lipoprotein kolesterol (LDL-K) parametrelerianaliz edildi.Bulgular: Plazma oreksin-A seviyelerinin, VKİ(r=-0,653, p

Relationship of Serum Orexin-A Levels with Obesity: A Cross-Sectional Association Study

Objective: The aim of this study is to assess the role of orexin-A hormone and its relationship with obesity in cohort of adults with obesity in work region. Material-Method: A total of 258 subject, aged 18-60 years, who applied to Sleep Disorder Centers of Medicine Faculty of Süleyman Demirel University and Isparta State Hospital Chest Disease and Sleep Laboratory of a city were taken into the study. According to their body mass index (BMI), subjects were grouped into five categories (normal weight, overweight, moderately obese, severely obese and morbidly obese). Results: Plasma samples from subjects were assayed for each plasma parameter using commercially available analytic systems. Plasma orexin-A levels correlated negatively with BMI (r=-0.653, p

PDF

___

1. Arora S. Role of Neuropeptides in Appetite Regulation and Obesity–a Review. Neuropeptides 2006; 40: 375-401.
2. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and Orexin Receptors: a Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors That Regulate Feeding Behavior. Cell 1998; 92: 573-585.
3. Rodgers RJ, Ishii Y, Halford JCG, Blundell JE. Orexins and Appetite Regulation. Neuropeptides 2002; 36: 303-325.
4. Digby JE, Chen J, Tang JY, Lehnert H, Matthews RN, Randeva HS. Orexin receptor expression in human adipose tissue: effects of orexin‐A and orexin‐B. J Endocrinol 2006; 191: 129–136.
5. Skrzypski M, Le TT, Kaczmarek P, Pruszynska-Oszmalek E, Pietrzak P, Szczepankiewicz D, et al. Orexin A stimulates glucose uptake, lipit accumulation and adiponectin secretion from 3T3-L1 adipocytes and isolated primary rat adipocytes. Diabetologia 2011; 54: 1841–1852. doi: 10.1007/s00125- 011- 2152-2.
6. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, et al. Genetic Ablation of Orexin Neurons in Mice Results in Narcolepsy, Hypophagia, and Obesity. Neuron 2001; 30: 345-354.
7. Kastin AJ, Akerstrom V. Orexin A but not Orexin B Rapidly Enters Brain from Blood by Simple Diffusion. Journal of Pharmacology and Experimental Therapeutics 1999; 289: 219-223.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 ; 342: 836–43.
9. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671–4.
10. Han KH, Hong KH, Park JH, Ko J, Kang DH, Choi KJ. C-reactive protein promotes monocyte chemoattractant protein-1--mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004; 109: 2566–71.
11. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14: 33–7.
12. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care 2018, 41 (Supplement 1), S13-S27.
13. Harayama T, Yoshida T, Yoshioka K, Kogure A, Sakai R, Yasui T, et al. Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients. Diabetol Int 2013; 4: 132–137.
14. Tuomilehto J, Lindström J, Eriksson JG, Valle T, Hamalainen H, Ilanne- Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350.
15. Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002; 25: 608–61.
16. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397–415.
17. Kissebah AH, Alfarsi S, Adams PW, Wynn V. The metabolic fate of plasma lipoproteins in normal subjects and in patients with insulin resistance and endogenous hypertriglyceridaemia. Diabetologia 1976; 12: 501–509.
18. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993; 42: 833–842.
19. Benditt EP, Hoffman JS, Eriksen N, Parmelee DC, Walsh KA. SAA, an apoprotein of HDL: its structure and function. Ann NY Acad Sci 1982; 389: 183–189.
20. Wu A, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 2004; 21: 210–221.
21. Tremollieres FA, Pouilles JM, Cauneille C, Ribot C. Coronary Heart Disease Risk Factors and Menopause, a Study in 1684 French Women. Atherosclerosis 1999; 142(2): 415-423.
22. Wilding JPH. Neuropeptides and Appetite Control. Diabetic Medicine 2002; 19(8): 619-627.
23. Yamanaka A, Sakurai T, Katsumoto T, Yanagisawa M, Goto K. Chronic Intracerebroventricular Administration of Orexin-A to Rats Increases Food Intake in Daytime, but has no Effect on Body Weight. Brain Research 1999; 849(1-2): 248-252.
24. Hajer GR, Van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959–71.
25. Koenig W, Sund M, Frohlich M, Fischer HG, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999; 99: 237-242.
26. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors. BMJ 1996; 312: 1061-1065;
27. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Arterioscler Thromb Vasc Biol 1997; 17: 1121-1127.
28. Haynes AC, Jackson B, Overend P, Buckingham RE, Wilson S, Tadayyon M, et al. Effects of Single and Chronic Intracerebroventricular Administration of the Orexins on Feeding in the Rat. Peptides 1999; 20(9): 1099-1105.
29. Rodgers RJ, Ishii Y, Halford JCG, Blundell JE. Orexins and Appetite Regulation. Neuropeptides 2002; 36(5): 303- 325.
30. Iqbal J, Henry BA, Pompolo S, Rao A, Clarke IJ. Longterm Alteration in Bodyweight and Food Restriction does not affect the Gene Expression of Either Preproorexin or Prodynorphin in the Sheep. Neuroscience 2003; 118(1): 217- 226.
31. Baranowska B, Wolinska-Witort E, Martynska M, Chmielowska M, Baranowska-Bik A. Plasma Orexin A, Orexin B, Leptin, Neuropeptide Y (NPY) and Insulin in Obese Women. Neuroendocrinology Letters 2005; 26(4): 293-296.
32. Adam JA, Menheere PPCA, Van Dielen FMH, Soeters PB, Buurman WA, Greve JWM. Decreased Plasma Orexin-A Levels in Obese Individuals. International Journal of Obesity 2002; 26(2): 274.
33. Beck B, Richy S. Hypothalamic Hypocretin/Orexin and Neuropeptide Y: Divergent Interaction with Energy Depletion and Leptin. Biochemical and Biophysical Research Communications 1999; 258(1): 119-122.
34. Horvath TL, Diano S, Van Den Pol AN. Synaptic Interaction Between Hypocretin, Orexin and Neuropeptide Y Cells in the Rodent and Primate Hypothalamus, a Novel Circuit Implicated in Metabolic and Endocrine Regulations. Journal of Neuroscience 1999; 19(3): 1072-1087.